Labcorp (LH)
(Delayed Data from NYSE)
$209.54 USD
+0.33 (0.16%)
Updated Mar 18, 2024 04:00 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LH 209.54 +0.33(0.16%)
Will LH be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for LH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LH
Labcorp (LH) Presents New Research on Precision Diagnostics
Labcorp (LH) Expands Strategic Alliances, Test Sales Fall
LH: What are Zacks experts saying now?
Zacks Private Portfolio Services
LH or COO: Which Is the Better Value Stock Right Now?
Are Investors Undervaluing Labcorp (LH) Right Now?
Labcorp (LH) Introduces Weight Loss Management Portfolio
Other News for LH
Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer
Fortrea Faces Challenges and Opportunities Post-LabCorp Spin-Off
Insider Sell: EVP, President Diagnostics & COO Mark Schroeder Sells Shares of Laboratory ...
Labcorp introduces weight loss management portfolio
Labcorp Launches Weight Loss Management Testing Solutions